Table 5 Previously published rates of toxicity following prostate SBRT
Study | n | Dose/fractions | Scale | Genitourinary toxicity | Gastrointestinal toxicity | ||
|---|---|---|---|---|---|---|---|
|  | Grade 2 |  ≥ Grade 3 | Grade 2 |  ≥ Grade 3 | |||
Kim [16] | 91 | 45–50/5 | CTCAE v.3 | Acute 22% Late 20.9% | Acute 0% Late 5.5% | Acute 20.9% Late 13.2% | Acute 2.2% Late 6.6% |
Madsen [21] | 40 | 33.5/5 | CTCAE v.2 | Acute 20.5% Late 20% | Acute 2.5% Late 0% | Acute 13% Late 7.5% | Acute 0% Late % |
Tang [22] | 30 | 35/5 | Â | Acute 13% | Acute 0% | Acute 7% | Acute 0% |
McBride [23] | 34 | 37.5–36.25/5 | CTCAE v.4 | Acute 19% Late 17% | Acute 0% Late 2% | Acute 7% Late 7% | Acute 0% Late 5% |
Alongi [24] | 40 | 35/5 | CTCAE v.4 | Acute 40% Late 2.5% | Acute 0% Late 0% | Acute 10% Late 0% | Acute 0% Late 0% |
Boyer [25] | 60 | 37/5 | CTCAE v.4 | Late 6.7% | Late 0% | Late 8.3% | Late 1.7% |
King [26] | 67 | 36.25/5 | RTOG | Late 5% | Late 3.5% | Late 2% | Late 0% |
Bolzicco [27] | 100 | 35/5 | RTOG | Late 3% Acute 12% | Late 1% Acute 0% | Late 1% Acute 18% | Late 0% |
Elias [28] | 84 | 35/5 | RTOG | Late 5.9% Acute 20.2% | Late 0% | Late 7.1% Acute 9.5% | Late 1.1% |
Katz [29] | 515 | 35–36.25/5 | RTOG | Late 9.1% Acute 4% | Late 1.7% Acute 0% | Late 4% Acute 4% | Late 4% Acute 0% |
Bernetich [30] | 142 | 35–36.25–37.5/5 | CTCAE v.3 | Late 14% Acute 28% | Late 2% Acute 2% | Late 3% Acute 4% | Late 0% Acute 0% |
Gurka [31] | 208 | 35–36.25/5 | CTCAE v.4 | Late 2.4% Acute 0.9% | Late 1.4% Acute 0% | N.A | N.A |
Seymour [32] | 56 | 38/4 | CTCAE v.4 | Late 19.6% Acute 35.7% | Late 3.6% Acute 0% | N.A | N.A |
Qi [33] | 86 | 40/5 | EPIC QoL | Obs/irrit MID: 46% Incont MID: 28% | N.A | N.A | N.A |
Kole [34] | 216 | 35–36.25/5 | IPSS | Late 13% | N.A | N.A | N.A |
Helou [35] | 259 | 35–40/5 | RTOG | Late 32.6% | Late 1.9% | Late 12.9% | Late 1.1% |
Zhang [36] | 78 | 38/4 | CTCAE v.4 | Late 19.2% | Late 2.6% | Â | Â |
Jackson [37] | 66 | 37/5 | CTCAE v.4 | Late 1.9% Acute 23% | Late 0% Acute 0% | Late 5% Acute 4% | Late 0% Acute 0% |
Musunuru [38] | 258 | 35–40/5 | CTCAE v.3 | N.A | N.A | Late 16.2% | Late 3.2% |
Miszczyk [39] | 400 | 36.25/5 | RTOG | Late 2.9% Acute 4% | Late 0% Acute 0.4% | Late 0.6% Acute 1.6% | Late 0.3% Acute 0.4% |
Zelefsky [40] | 551 | 35–40/5 |  | Late 21.1% Acute 10% | Late 2.5% Acute 0.7% | Late 3.4% Acute 1.8% | Late 0.4% Acute 0% |
Current series | 15 | 38/4 40/5 | CTCAE v.5 | Acute 0% Late 0% | Acute 0% Late 0% | Acute 0% Late 0% | Acute 0% Late 0% |